-
Eli Lilly Acquires Orna Therapeutics to Pioneer In Vivo Cell Engineering and Advance Next-Generation Therapies
NYSE: $LLY Eli Lilly and Company has announced a significant strategic move to bolster its capabilities in advanced therapeutics by entering into a definitive agreement to acquire Orna Therapeutics, Inc. This acquisition focuses on integrating Orna’s innovative platform for engineering immune cells directly within the body, aiming to revolutionize the treatment landscape for various diseases,…
-
Sanofi’s $2.2 Billion Bet: What Their Acquisition of an HBV Vaccine Maker Means for Global Health
NASDAQ: $SNY In a move that sent ripples through the pharmaceutical landscape, Sanofi recently announced its acquisition of a Hepatitis B (HBV) vaccine maker for a staggering $2.2 billion. This strategic purchase, detailed in a recent article from Pharmaceutical Technology, isn’t just a financial transaction; it represents a significant investment in global public health and…